Navigation Links
Labopharm reports results for Phase III study on twice-daily tramadol-acetaminophen formulation
Date:4/2/2009

LAVAL, QC, April 2 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced the results of its recently completed North American Phase III clinical trial for its twice-daily formulation of tramadol and acetaminophen (study 06CCL3-001).

Study 06CCL3-001 was a multi-centre, randomized, double-blind, parallel-arm study that compared the efficacy and safety of Labopharm's twice-daily tramadol-acetaminophen formulation to placebo in the treatment of moderate to severe acute low back pain. A total of 277 patients were included in the study. Thirteen percent (13%) of patients in the active treatment group discontinued early (12% due to adverse events) and 5% of patients in the placebo group discontinued early (2% due to adverse events).

Results of the efficacy measures in the study demonstrated a statistically significant difference from placebo in some cases but not in others. An analysis of covariance demonstrated a statistically significant difference from placebo on the Sum of Pain Intensity Differences (SPID) over 50 hours using LOCF (last observation carried-forward) as the imputation method, however, the results were not statistically significant using LOCF/BOCF (baseline observation carried-forward), the primary endpoint. A non-parametric analysis, however, demonstrated statistical significance using both LOCF and LOCF/BOCF as imputation methods. The difference from placebo on the Total Pain Relief (TOTPAR) score was also statistically significant using both LOCF and LOCF/BOCF imputation methods and the patients' global impression of the effectiveness of the study medication was statistically different from placebo. Statistical significance reflects a p-value of less than 0.05 in each of the analyses.

Regulatory authorities throughout the world have different requirements for the analysis and demonstration of efficac
'/>"/>

SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ... August 04, 2015 , ... ... whose cancer has come back: Retreatment may be a viable option. Surviving Mesothelioma ... it now. , According to surgeons at the University of New South ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... and other long-term care facilities, today announced details of the Advanced level of ... and centers. , Providigm’s QAPI Accreditation program , introduced in 2013, is ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... finds the North America IT reseller channel will grow at least 6 percent ... of their 2014 pace and greater than their OEM/vendor partners. , The ...
(Date:8/4/2015)... ... August 04, 2015 , ... Driving skills may decline ... driving, says the August 2015 Harvard Health Letter. , "Age and health conditions ... an individual assessment of skills," says Lissa Kapust, a social worker at Harvard-affiliated ...
(Date:8/4/2015)... ... August 04, 2015 , ... Updated enrollment data on the top U.S. health ... be accessed at http://www.AISHealth.com . The data is free to all registered users ... tables and charts on the website’s “Data” section include:, , ...
Breaking Medicine News(10 mins):Health News:New Research Reveals Some Patients Experience Extended Mesothelioma Survival with Repeat Treatment, According to Surviving Mesothelioma 2Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 2Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 3Health News:The 2112 Group Forecasts North America IT Channel to Grow At Least 6% in 2015 2Health News:The 2112 Group Forecasts North America IT Channel to Grow At Least 6% in 2015 3Health News:Assessment Can Help Older Drivers Keep Driving Safely, from the August 2015 Harvard Health Letter 2Health News:Atlantic Information Services Website Offers Up-to-Date U.S. Health Plan Enrollment Data 2
... in West Virginia to control obesity in children. The public schools ... a large scale. The game // involves a player moving his/her ... screen. Children aged between 10 years and 14 years will be ... ,West Virginia has turned to computer games to make school children ...
... Wall Street Journal studied about the effects of stress on the pregnant ... number of researches is being conducted on stress and people are in ... ,There is an increase in the number of pregnant women approaching ... ,Hence there is a need to include new ...
... out to be negative for the presence of Japanese ... the health minister Datuk Dr Chua Soi Lek. The ... ,The victim, Norhayati Awang is currently being ... Perempuan Zainab II. According to official reports, she is ...
... by Australian researchers could pave way for an improvement in ... of lung cancer with a high mortality rate. The promising ... definitive diagnosis of lung cancer. ,The study participants were ... rate for these patients was projected to be less than ...
... Food and Drug Administration (FDA) against the seafood processing ... // This will effectively stop the company from ... fish is reported to be contaminated, as a result ... ,The inspections conducted by the FDA in 2004 ...
... Madras Institute of Trauma, more familiarly known as MIOT ... system of a city in Germany, aimed at sharing ... ,MIOT signed a memorandum of understanding ... Stuttgart's public healthcare system is entering into such a ...
Cached Medicine News:Health News:New Treatment Offers Hope For Lung Cancer Patients 2
(Date:8/4/2015)...  The Pittsburgh Life Sciences Greenhouse (PLSG), the region,s ... one of its portfolio companies, Medrobotics Corporation, has received ... Robotic System in the U.S.  "I ... said John W. Manzetti , president and CEO ... since spinning out of The Robotics Institute at Carnegie ...
(Date:8/4/2015)...  MEI Pharma, Inc. (Nasdaq: MEIP ), an oncology ... cancer, announced today that Daniel P. Gold , Ph.D., ... Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2015 at ... in New York . A live webcast ... A replay will be available approximately one hour after the ...
(Date:8/4/2015)... , Aug. 4, 2015  Armada ... of Massachusetts Medical School,s Clinical Pharmacy Services ... regarding clinical protocols and therapy interventions within ... Specialty medication therapy management is ... to ensure optimal patient outcomes are achieved ...
Breaking Medicine Technology:Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 2Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 3MEI Pharma to Present at Wedbush PacGrow Healthcare Conference 2Armada Health Care collaborates with University of Massachusetts Medical School for ArmadaOne Specialty Pharmacy Platform 2Armada Health Care collaborates with University of Massachusetts Medical School for ArmadaOne Specialty Pharmacy Platform 3
... LAKE FOREST, Ill., May 24, 2012   Hospira, ... leading provider of injectable drugs and infusion technologies, ... of I.V. clinical integration of infusion pumps and ... Technology Management Week, which recognizes the important work ...
... England and MILAN, May 24, 2012 Mylan Inc. (Nasdaq: ... Italy-based subsidiaries have launched Ibandronic Acid Film Coated Tablets POM, ... ® Tablets, a treatment for osteoporosis(1). ... generic for Mylan,s businesses in the UK and Italy. We ...
Cached Medicine Technology:I.V. Clinical Integration Helps Deliver Safety, Efficiency And Financial Benefits; Hospira Shares Snapshot Of Results, Process 2I.V. Clinical Integration Helps Deliver Safety, Efficiency And Financial Benefits; Hospira Shares Snapshot Of Results, Process 3Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy 2
... The Ray TFC Unite Device is the ... The Ray TFC Unite device features the same ... contact offered by fenestrations is paramount in the ... the Ray TFC Unite system promotes load sharing ...
... The INTER FIX and ... Devices are designed to maximize ... of the implant. Both the ... RP Threaded Fusion devices combine ...
... Confirmatory (Western Blot): The Genetic Systems HIV-1 ... for the detection of antibodies to HIV-1. The ... of HIV-1 grown in the CEM cell line. ... devoid of HLA Class ll antigens, helps reduce ...
Prognosis / Patient Management. HIV-1 Viral Load Assay. NucliSens HIV-1 QT covers the entire dynamic range of viral load testing from a single patient sample, without reflex testing or thermalcycli...
Medicine Products: